Activated synovial macrophages as targets for osteoarthritis drug therapy

Current Drug Targets

Volumn 11, Issue 5, 2010, Pages 576-585

  Bondeson, Jan ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Aggrecanase; Interleukin 1; Macrophage; Matrix metalloproteinase; Osteoarthritis; Synovium; Tumour necrosis factor alpha

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA;

BONE EROSION; BONE INJURY; CARTILAGE DEGENERATION; DRUG TARGETING; HUMAN; MACROPHAGE ACTIVATION; NONHUMAN; OSTEOARTHRITIS; OSTEOPHYTE; PANNUS; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN-1; MACROPHAGES; MODELS, IMMUNOLOGICAL; OSTEOARTHRITIS; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951045313     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791011965     Document Type: Review

References (70)

1. Kinne RW, Stuhlmuller B, Burmester G-R. Cells of the synovium in rheumatoid arthritis: macrophages. Arthritis Res Ther 2007; 9: 224. (Pubitemid 351866027)
2. Feldmann M, Maini RN. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223: 7-19. (Pubitemid 351986171)
3. Clark AG, Jordan JM, Vilim V, et al. Serum cartilage oligomeric protein reflects osteoarthritis presence and severity. Arthritis Rheum 1999; 42: 2356-2364
4. Sowers M, Jannausch M, Stein E, Jamadar D, Hochberg M, Lachance L. C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis Cartil 2002; 10: 595-601. (Pubitemid 34993944)
5. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64: 1263-1267 (Pubitemid 41206240)
6. Farahat MN, Yanni G, Poston R, Panayi GS. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1993; 52: 870-875 (Pubitemid 24019143)
7. Bondeson J, Foxwell BMJ, Brennan FM, Feldmann M. A new approach to defining therapeutic targets: blocking NFκB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium, but spares anti-inflammatory mediators. Proc Natl Acad Sci USA 1999; 96: 5668-5673 (Pubitemid 29234676)
8. Amos N, Lauder S, Evans A, Feldmann M, Bondeson J. Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IκBα reveals that most, but not all, inhibitory and destructive mediators, are NFκB dependent. Rheumatology 2006; 45: 1201-1209 (Pubitemid 44542060)
9. Blom AB, van den Berg WB. The synovium and its role in osteoarthritis. In Bronner F, Farach-Carson MC Eds, Bone and Osteoarthritis. Berlin, Springer Verlag 2007; 4: 65-79.
10. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid athritis. J Clin Invest 2008; 118: 3537-3545
11. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002; 39: 237-246
12. Abramson SB, Yaziki Y. Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Adv Drug Deliv Rev 2006; 58: 212-225
13. Pelletier J-P, Martel-Pelletier J. New trends in the treatment of osteoarthritis. Semin Arthritis Rheum 2005; 34: 13-14
14. Berenbaum F. The quest for the holy grail: a disease-modifying osteoarthritis drug. Arthritis Res Ther 2007; 9: 111. (Pubitemid 350278746)
15. Qvist P, Bay-Jensen A-C, Christiansen C, Dam BE, Pastoreau P, Karsdal MA. The disease modifying osteoarthritis drug (DMOAD): Is it on the horizon? Pharmacol Res 2008; 58: 1-7.
16. Haywood L, McWilliams DF, Pearson CI, et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003; 48: 173-177
17. Foxwell BMJ, Browne KA, Bondeson J, et al. Efficient adenoviral infection with IκBα reveals that macrophage TNFα production in rheumatoid arthritis is NFκB dependent. Proc Natl Acad Sci USA 1998; 95: 8211-8215 (Pubitemid 28326092)
18. Bondeson J, Browne KA, Brennan FM, Foxwell BMJ, Feldmann M. Selective regulation of cytokine induction by adenoviral gene transfer of IκBα into human macrophages: lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is NFκB independent. J Immunol 1999; 162: 2939-2945 (Pubitemid 29309322)
19. Hayes AL, Smith C, Foxwell BM, Brennan FM. CD45-induced tumor necrosis factor alpha production in monocytes is phosphatidylinositol 3-kinase-dependent and nuclear factor kappaB-independent. J Biol Chem 1999; 274: 33455-33461 (Pubitemid 129511652)
20. Brennan FM, Hayes AL, Ciesielski CJ, Green P, Foxwell BMJ, Feldmann M. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells. Arthritis Rheum 2002; 46: 31-41.
21. Andreakos E, Smith C, Kiriakidis S, et al. Heterogenous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy. Arthritis Rheum 2003; 48: 1901-1912 (Pubitemid 36828685)
22. Shahrara S, Castro-Rueda HP, Haines GK, Koch AE. Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissue. Arthritis Res Ther 2007; 9: R112.
23. Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006; 8: R187. (Pubitemid 46211006)
24. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNFa antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; ii: 244-247 (Pubitemid 19180612)
25. Bondeson J, Wainwright S, Hughes C, Caterson B. The regulation of ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin Exp Rheumatol 2008; 26: 139-145 (Pubitemid 351385270)
26. Blom AB, van Lent PLEM, Holthuysen AEM, et al. Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritis. Osteoarthritis Cartil 2004; 12: 627-635
27. Van Lent PLEM, Blom AB, van der Kraan P, et al. Cricial role of synovial lining macrophages in the promotion of transforming growth factor beta-mediated osteophyte formation. Arthritis Rheum 2004; 50: 103-111
28. Blom AB, van Lent PL, Libregts S, et al. Crucial role of macrophages in matrix metalloproteinase-mediated cartilage destruction during experimental osteoarthritis. Arthritis Rheum 2007; 56: 147-157
29. Marini S, Fasciglione GF, Monteleone G, Maiotti M, Tarantino U, Coletta G. A correlation between knee cartilage degradation observed by arthroscopy and synovial proteinases activity. Clin Biochem 2003; 36: 295-304. (Pubitemid 36700453)
30. Bau B, Gebhard PM, Haag J, Knorr T, Bartnik E, Aigner T. Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum 2002; 46: 2648-2657 (Pubitemid 36118928)
31. Pratta MA, Scherle PA, Yang G, Liu RQ, Newton RC. Induction of aggrecanase-1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced protein. Arthritis Rheum 2003; 48: 119-133 (Pubitemid 36091656)
32. Bondeson J, Lauder S, Wainwright SD, et al. Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are NFkappaB dependent. J Rheumatol 2007; 34: 523-533 (Pubitemid 46364007)
33. Glasson SS, Askew R, Sheppard B, et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum 2004; 50: 2547-2558 (Pubitemid 39062716)
34. Glasson SS, Askew R, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005; 434: 644-648 (Pubitemid 40488556)
35. Stanton H, Rogerson FM, East CJ, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005; 434: 648-652 (Pubitemid 40488557)
36. East CJ, Stanton H, Golub SB, Rogerson FM, Fosang AJ. ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate rich region of aggrecan. J Biol Chem 2007; 282: 8632-8640 (Pubitemid 47093500)
37. Zwerina J, Redlich K, Polzer K, et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007; 104: 11742-11747 (Pubitemid 47175083)
38. Stewart MC, Fosang AJ, Bai Y, Osborn B, Plaas A, Sandy JD. ADAMTS5-mediated aggrecanolysis in murine epiphyseal chondrocyte cultures. Osteoarthritis Cartil 2006; 14: 392-402.
39. Song R-H, Tortorella MD, Malfait A-M, et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS4 and ADAMTS5. Arthritis Rheum 2007; 56: 575-585 (Pubitemid 46271983)
40. Wachsmuth L, Bau B, Fan Z, Pecht A, Gerwin N, Aigner T. ADAMTS-1, a gene product of articular chondrocytes in vivo and in vitro, is downregulated by interleukin 1beta. J Rheumatol 2004; 31: 315-320
41. Kevorkian L, Young DA, Darrah C, et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 2004; 50: 131-141 (Pubitemid 38084297)
42. Gendron C, Kashiwagi M, Lim NH, et al. Proteolytic activities of human ADAMTS-5. Comparative studies with ADAMTS-4. J Biol Chem 2007; 282: 18294-18306 (Pubitemid 47100219)
43. Feldmann M, Andreakos E, Smith C, et al. Is NF-kappa B a useful therapeutic target in rheumatoid arthritis? Ann Rheum Dis 2002; 61: 13-18
44. Saklatvala J. Inflammatory signaling in cartilage: MAPK and NF-kappa B pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Curr Drug Targets 2007; 7: 305-313 (Pubitemid 46299678)
45. Goldring MB. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Pract Res Clin Rh 2006; 20: 1003-1025
46. Brown KK, Heitmeyer SA, Hoofkin EB, et al. P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm 2008; 5: 22.
47. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW. Treatment of equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002; 9: 12-20.
48. Chen LX, Lin L, Wang HJ, et al. Suppression of early experimental osteoartritis by in vivo delivery of the adenoviral vector-mediated NFkappaB-specific siRNA. Osteoarthritis Cartil 2008; 16: 174-184
49. Malemud CJ. Cytokines as therapeutic targets for osteoarthritis. Biodrugs 2004; 18: 23-35.
50. Blom AB, van der Kraan PM, van den Berg WB. Cytokine targeting in osteoarthritis. Curr Drug Targets 2007; 8: 283-292
51. Burger D, Dayer J-M, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006; 20: 879-896
52. Kalliolias GD, Liossis SNC. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 2008; 17: 349-359 (Pubitemid 351578187)
53. Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, van den Berg W. Pralnacasan, an inhibitor of interleukin-1 converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartil 2003; 11: 738-746 (Pubitemid 37184492)
54. Pavelka K, Trc T, Karpas K, et al. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee. Arthritis Rheum 2007; 56: 4055-4064
55. Grunke M, Schulze-Koops H. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Ann Rheum Dis 2006; 65: 555-556
56. Magnano MD, Chakravarty EF, Broudy C, et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007; 34: 1323-1327 (Pubitemid 46898115)
57. Güler-Yüksel M, Kloppenburg M, Allaart CF, et al. Infliximab might be protective against progressive radiographic interphalangeal osteoarthritis. Osteoarthritis Cartil 2008; 16 (Suppl 4): S228.
58. Chevalier X, Girardeau B, Conzorier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005; 32: 1317-1323 (Pubitemid 40995389)
59. Goupille P, Mulleman D, Chevalier X. Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience. Arthritis Res Ther 2007; 9: 110. (Pubitemid 350263457)
60. Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, double-blind, placebo-controlled study. Arthritis Care Res 2009; 61: 344-352
61. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50: 1412-1419 (Pubitemid 38608062)
62. 11C-(R)-PK11195 and positron emission tomography. Arthritis Rheum 2008; 58: 3350-3355
63. van der Heijden JW, Oerlemans R, Dijkmans BAC, et al. Folate receptor γ as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 2009; 60: 12-21.
64. Maini RN, Feldmann M. The pitfalls in the development of biologic therapy. Nat Clin Practice Rheumat 2007; 3: 1.
65. Feldmann M. Translating molecular insights in autoimmunity into effective therapy. Annu Rev Immunol 2009; 27: 1-27.
66. Tortorella MD, Malfait AM. Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis. Curr Pharm Biotechnol 2008; 9: 16-23.
67. Hatano E, Fujita T, Ueda Y, et al. Expression of ADAMTS-4 (aggrecanase-1) and possible involvement in regression of lumbar disc herniation. Spine 2006; 31: 1426-1432 (Pubitemid 43880188)
68. Wagsater D, Bjork H, Zhu C, et al. ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. Atherosclerosis 2008; 196: 514-522
69. Wainwright SD, Bondeson J, Hughes CE. An alternatively spliced transcript of ADAMTS4 is present in human synovium from osteoarthritis patients. Matrix Biol 2006; 25: 317-320 (Pubitemid 43912424)
70. Blom AB, Brockbank SM, van Lent PL, et al. Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: prominent role of Wnt-induced signaling protein 1. Arthritis Rheum 2009; 60: 501-512